▶ 調査レポート

尿失禁治療装置の世界市場2021-2026:成長・動向・新型コロナの影響・市場予測

• 英文タイトル:Urinary Incontinence Treatment Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Mordor Intelligenceが調査・発行した産業分析レポートです。尿失禁治療装置の世界市場2021-2026:成長・動向・新型コロナの影響・市場予測 / Urinary Incontinence Treatment Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026) / MRC2108A465資料のイメージです。• レポートコード:MRC2108A465
• 出版社/出版日:Mordor Intelligence / 2021年7月31日
• レポート形態:英文、PDF、112ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥629,000 (USD4,250)▷ お問い合わせ
  Team User¥703,000 (USD4,750)▷ お問い合わせ
  Corporate License¥1,110,000 (USD7,500)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Mordor Intelligence社は、尿失禁治療装置の世界市場規模が2020年3,175.41百万ドルから2026年4,663.88百万ドルまで、2021年から2026年の間に年平均6.57%成長すると予測しています。本調査資料では、世界の尿失禁治療装置市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別(尿道スリング、電気刺激装置、人工尿道括約筋、カテーテル、その他)分析、エンドユーザー別(病院、外来手術センター、その他)分析、地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)、競争状況、市場機会/将来の見通しなどを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・尿失禁治療装置の世界市場規模:製品別(尿道スリング、電気刺激装置、人工尿道括約筋、カテーテル、その他)
・尿失禁治療装置の世界市場規模:エンドユーザー別(病院、外来手術センター、その他)
・尿失禁治療装置の世界市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争状況(Boston Scientific Corporation、Becton, Dickinson and Company、Colopast AS.、Promedon Group、A.M.I. GmbH、Johnson & Johnson、Zephyr Surgical Implants、Medtronic PLC、Caldera Medical Inc、Hollister Incorporated、Nipro Corporation、Karl Storz SE & Co. KG、B Braun Melsungen AG、Baxter International Inc、ConvaTec Group Plc)
・市場機会/将来の見通し

The Urinary Incontinence Treatment Devices Market was valued at USD 3,175.41 million in 2020 and is expected to reach 4,663.88 billion by 2026, registering a CAGR of 6.57% during the forecast period.

In the initial days of the COVID-19 pandemic 2020, several countries were in lockdown. They suspended trade with other countries and implemented travel restrictions, leading to the decline in diagnosis and surgical procedures in the first half of 2020.

According to the study published in the British Journal of Surgery, in May 2020, based on a 12-week period of peak disruption to hospital services due to COVID-19, around 28.4 million elective surgeries worldwide were canceled or postponed in 2020. In addition, more than 580,000 planned surgeries in India were canceled or delayed as a result of the COVID-19 pandemic, according to a study conducted by an international consortium in May 2020.

According to a research article by Ahmed Al-Jabir et al., published in International Journal of Surgery July 2020, globally, during COVID-19 pandemic 2020, some of the urological procedures which were delayed or postponed include urinary incontinence, stress incontinence, overactive bladder (OAB) and neurogenic bladder. In case of chronic catheter change it was delayed for 2–4 weeks, respectively.

The major factor attributing to the growth of the market is the rising prevalence of urinary incontinence. Numerous factors such as urinary tract infection, weakening of pelvic floor muscles and urethral sphincters, menopause, pregnancy and childbirth and post radical prostatectomy surgery in men lead to the development of urinary incontinence symptoms. According to the Gothenburg Continence Research Center, in 2018 more than 423 million people suffered from urinary incontinence of which, 303 million were women.

According to the National Center for Biotechnology Information (NCBI), in the article titled ‘Urinary Incontinence in Postmenopausal Women (2019)’, it was found that there is a rise in the incidence of various diseases, such as Parkinson’s disease, diabetes, multiple sclerosis etc., which may lead to increased prevalence of urinary incontinence in males and females. This is expected to increase demand for urinary incontinence treatment devices over the forecast period. Furthermore, rising demand for minimally invasive procedures and increasing technological advancements boost the market growth.

Moreover, the market players are adopting various strategies, such as product launches, developments, acquisitions, merges, and collaborations, to expand their product portfolio in the market studied, and is boosting the market growth. For instance, in February 2018, Cogentix Medical Inc. announced the commercialization of an urgent PC neuromodulation system (electric stimulation device) for the treatment of urge incontinence.

However, factors such as lack of awareness about devices and social stigma associated with the disease, and the risks and complications related to the procedures, are expected to impede market growth over the forecast period.

Key Market Trends

Urethral Slings Segment is Expected to Witness a Healthy Growth Rate Over the Forecast Period

Urethral slings are highly recommended for surgical treatment for treating stress urinary incontinence. The urethral sling is considered the gold standard method that has replaced all conventional procedures, such as colposuspension and vaginal mesh.

According to a 2020 research study by Jeremy Yuen-Chun Teoh et al., titled ‘A Global Survey on the Impact of COVID-19 on Urological Services’, outpatient clinics for female urinary incontinence, benign prostatic hyperplasia, infertility, and sexual medicine, benign scrotal conditions, renal stone, and bladder stone were most affected. Moreover, there was significant cut-down across various types of outpatient investigations and procedures during COVID-19 pandemic 2020, particularly surgical procedures for female urinary incontinence, infertility, renal stones, and bladder stones had the highest rates of cut-down services.

Urethral slings surgery is also known as mid-urethral sling surgery. Mid-urethral sling surgery usually takes around 30 minutes to perform and is considered an outpatient procedure. In this surgery, a sling is placed around the urethra to lift it back into a normal position and exert pressure on the urethra to aid urine retention. The sling is attached to the abdominal wall.

The sling material may be muscle, ligament, or tendon tissue taken from the woman or from an animal, such as a pig. It may also be composed of synthetic material, such as plastic that is compatible with body tissues or of absorbable polymer that disintegrates over time.

According to the Gothenburg Continence Research Center, in 2018, more than 423 million people suffered from urinary incontinence, of which 303 million were women. The rising prevalence of urinary incontinence among the women population is increasing the demand for urethral sling surgery.

Furthermore, benefits such as quick recovery time are increasing its demand among patient population. Apart from the low-risk rates and advantages of the sling procedures, the increasing demand for minimally invasive surgeries is also boosting the segment growth.

In February 2019, the company Boston Scientific had launched a redesign of its mesh sling system, which is a surgical implant for stress urinary incontinence in male patients. In addition, the surgical mesh is implanted to support the urethra or bladder neck in order to correct stress urinary incontinence (SUI).

Moreover, the growing volume of urinary incontinence and cumulative research in the arena of urinary incontinence treatment adoptions are the major factors for the growth of the urethral slings segment.

North America is Expected to Hold a Significant Share in the Market Over the Forcasted Period

The major driving factors attributing to the market growth in North America region are increasing the prevalence of urinary incontinence, increasing geriatric population, and the increasing demand for minimally invasive surgeries in the region.

Some of the market players recorded a revenue decline in the urology platform due to the COVID-19 outbreak. For instance, Coloplast Corp., interventional urology segment generated a negative organic growth of -7% in the financial year 2019-20. The negative growth was mainly due to a decrease in sales of Altis single-incision slings and other products, due to the cancellation of elective surgeries and procedures in the United States due to the COVID-19 outbreak. Moreover, due to the COVID-19 outbreak, the elective procedures outside of the United States were also postponed in several countries.

Furthermore, due to the improved outlook for the interventional urology segment, the company’s commercial investments were temporarily put on hold due to the COVID-19 pandemic. These investments were initiated again during Q4-2020.

As per the Government of Canada’s statistics report, as of July 2019, Canadian geriatric population included 6,592,611 people, which accounted for 17.5% of the Canadian population. The proportion of seniors in Canada has been increasing over time. Aging increases the risk of bladder problems such as bladder control issues, such as leakage or urinary incontinence thereby positively influencing the Canadian market for urinary incontinence treatment devices market.

As per the article published in Medscape in June 2021 on “What is the prevalence of urinary incontinence?”, the Urinary incontinence has been estimated to affect 10-13 million people in the United States. Also, the cost of treating urinary incontinence in United States alone is USD 16.3 billion, 75% of which is spent on treatment of women.

Companies adopting strategies, such as research and development, mergers and acquisitions, and product launches, are being adopted by domestic companies to strengthen their market position. In February 2020, Atlantic Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted over-the-counter (OTC) clearance to INNOVO, a non-invasive, clinically proven and wearable device for the treatment of stress urinary incontinence (SUI) in adult females.

Competitive Landscape

The Urinary Incontinence Treatment Devices market is moderately competitive. Some of the companies which are currently dominating the market are Boston Scientific Corporation, Becton, Dickinson and Company., Coloplast Corp, Promedon Group, A.M.I. GmbH, Johnson & Johnson, ZSI Surgical Implants S.R.L.,Medtronic plc, Hollister Incorporated.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
レポート目次

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Urinary Incontinence and Rise in Geriatric Population
4.2.2 Rise in Demand for Minimally Invasive Surgery and Product Development
4.3 Market Restraints
4.3.1 Lack of Awareness about Devices and Social Stigma Associated with the Disease
4.3.2 Risks and Complications from the Procedures
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Urethral Slings
5.1.2 Electrical Stimulation Devices
5.1.3 Artificial Urinary Sphincters
5.1.4 Catheters and Others
5.2 By End-User
5.2.1 Hospitals
5.2.2 Ambulatory Surgical Centres
5.2.3 Other End-Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Boston Scientific Corporation
6.1.2 Becton, Dickinson and Company
6.1.3 Colopast AS.
6.1.4 Promedon Group
6.1.5 A.M.I. GmbH
6.1.6 Johnson & Johnson
6.1.7 Zephyr Surgical Implants
6.1.8 Medtronic PLC
6.1.9 Caldera Medical Inc
6.1.10 Hollister Incorporated
6.1.11 Nipro Corporation
6.1.12 Karl Storz SE & Co. KG
6.1.13 B Braun Melsungen AG
6.1.14 Baxter International Inc
6.1.15 ConvaTec Group Plc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS